Avastin
<p><span class="postbody"><span class="postbody"><a href="http://www.docguide.com/news/content.nsf/news/852571020057CCF68525728A0056E3F7" target="_blank"><font color="#000066">http://www.docguide.com/news/content.nsf/news/852571020057CCF68525728A0056E3F7</font></a><br/><br/>BASEL, SWITZERLAND – February 22, 2007 -- A phase III study of Avastin (bevacizumab) and chemotherapy improved progression free survival in patients with previously untreated advanced non-small cell lung cancer (NSCLC), the most common form of the disease. <br/><br/>This benefit was seen in patients who received either one of two different Avastin doses investigated in the trial. <br/><br/>The results show that Avastin administered in a schedule of either 7.5 or 15 mg/kg every 3 weeks in combination with gemcitabine/cisplatin chemotherapy significantly prolonged the time patients with advanced NSCLC lived without their disease progressing when compared to chemotherapy alone. <br/><br/>Although the study was not designed to compare the Avastin doses, a similar treatment effect in progression-free survival was observed between the two arms. The benefit and relative safety of each arm will be presented at an upcoming medical meeting. There were no new safety signals associated with the use of Avastin at either dose in this clinical setting. <br/><br/>The study is an international Phase III trial which includes more than 1,000 patients with previously untreated advanced NSCLC, the most common form of lung cancer, with histology other than predominant squamous cell. The primary objective of the study was to demonstrate superiority in progression-free survival of both Avastin containing treatment arms versus the control regimen.<br/></span></span></p> <font size="3">我也一直非常关注阿瓦司汀的药理和药效，但是国内的一线数据太少了，病友实际使用经验反馈更是少，希望能多了解一下国外在阿瓦司汀的使用情况。</font>
[此贴子已经被作者于2007-3-14 0:07:26编辑过] <p>Please see more information below:</p><p><span class="posted" nd="1">Posted on: Friday, 13 October 2006, 06:00 CDT</span>
</p><h1>Avastin Approved for Lung Cancer</h1><p nd="2">The FDA has approved Genentech's cancer drug Avastin to be used in combination with carboplatin and paclitaxel chemotherapy for the first-line treatment of patients with lung cancer. </p><p nd="3">Avastin will be used to specifically target non-small cell lung cancer, the most common type of lung cancer. The approval is based on a phase III study that showed Avastin in combination with chemotherapy resulted in a 25% improvement in overall survival compared to chemotherapy alone. </p><p nd="4">"Bevacizumab, in combination with chemotherapy, is the first therapy in 10 years to improve on standard first-line treatment for advanced lung cancer and the first FDA-approved therapy ever to extend survival for these patients beyond one year," said Alan Sandler, director of Medical Thoracic Oncology at Vanderbilt-Ingram Cancer Center. </p><div style="FLOAT: right; MARGIN: 10px 0px 10px 10px; WIDTH: 300px;"><script language="JavaScript" src="http://an.tacoda.net/an/11620/slf.js"></script><script language="JavaScript"></script><script language="JavaScript" src="http://anad.tacoda.net/cgi-bin/ads/ad11620a.cgi/v=2.1S/sz=300x250a/NZ/91560/NF/RETURN-CODE/JS/"></script><a href="http://anad.tacoda.net/ads/ad11620a-map.cgi/BCPG65771.94390.107785/SZ=300X250A/V=2.1S//REDIRURL=http://www.emcinsignia.com/en/promos/retrospect/?utm_id=119" target="_blank"></a></div><p nd="5">Genentech also said that it plans to initiate a first-of-its-kind program to cap the overall expense of Avastin to $55,000 per year per eligible patient for any FDA-approved indication. </p><p nd="6">The price of Avastin was established in February 2004 upon the FDA approval of the drug for the treatment of first-line colorectal cancer in combination with chemotherapy. At that time, the monthly price of Avastin was set below the standard of care chemotherapy for metastatic colorectal cancer at approximately $4,400. </p><p nd="7">In advanced lung cancer, a higher dose of Avastin is indicated which means the monthly price of Avastin has to be increased. </p><p nd="8">"The new expenditure cap on Avastin is a step Genentech is taking to address this variability in current and future FDA-approved indications," said Arthur Levinson, Genentech's chairman and CEO.</p><p><br/></p><p nd="9">Source: Datamonitor</p> <div id="result_box" dir="ltr">巴塞尔，瑞士-2 007年2月2 2日-第三阶段的研究阿瓦斯丁（贝伐单抗）和化疗改善级数免费病人的存活率与以前未经治疗晚期非小细胞肺癌（N S CLC），是最常见的一种疾病。 <br/><br/>这项福利被认为是在病人接受其中一两个不同的阿瓦斯丁剂量调查，在此试验。 <br/><br/>结果表明，阿瓦斯丁在经管的时间表，无论是7.5或15毫克/公斤，每3周，结合吉西他滨/顺铂化疗显着延长时间治疗晚期非小细胞肺癌的生活没有他们的疾病进展的时候相比，单用化疗。 <br/><br/>虽然这项研究并不是用来比较阿瓦斯丁剂量，一项类似的治疗效果，在级数无生存观察到两国之间的武器。福利和相对安全的每一个手臂将提交给即将举行的医学会议。有没有新的安全信号与使用阿瓦斯丁购买剂量在本临床设定。 <br/><br/>这项研究是一个国际性的第三阶段试验，其中包括了超过1000例初治晚期非小细胞肺癌，是最常见的一种肺癌，是学以外为主，鳞状细胞。这项研究的主要目的是，要表现出优势，循序渐进无生存的阿瓦斯丁都含有治疗武器银两控制水情。</div>
页:
[1]